Gilead Sciences, Inc.

GILDleader

Gilead Sciences is a research-based biopharmaceutical company that revolutionized the treatment of HIV and hepatitis C. Biktarvy has become the most prescribed HIV treatment globally, and the company is expanding aggressively into oncology through its Kite cell therapy division and antibody-drug conjugate platform.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($28.1B)

Datos estáticos (cargando finanzas en tiempo real…)

HIV (Biktarvy, Descovy) (55%)

Oncology (Trodelvy, Yescarta) (18%)

Liver Disease (HCV/HBV) (10%)

Veklury & Other (17%)

Composición de segmentos y clientes principales

Detalles del producto

Biktarvy45%

Leading single-tablet HIV regimen combining three antivirals

Veklury (Remdesivir)10%

Antiviral treatment for COVID-19 and emerging viral threats

Trodelvy/Cell Therapy25%

Oncology portfolio including ADCs and CAR-T via Kite Pharma

Relaciones en la Cadena de Suministro

Competidores

Pfizer Inc.

Antiviral therapies

Impacto: Competing in antivirals

AbbVie Inc.

Oncology pipeline overlap

Impacto: Competing in oncology

Socios

Moderna, Inc.

Potential mRNA-based HIV vaccine collaboration

Impacto: Research partnership

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Gilead Sciences, Inc. impulsado por IA.

Información de la Empresa

Sede Central

Foster City, California, USA

Fundación

1987

Empleados

18,000+

Sitio Web

gilead.com

Estado del sector — 제약 / 바이오

Noticias del sector